Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2002
03/14/2002WO2002020090A2 Pharmaceutical compositions
03/14/2002WO2002020060A1 Vp22 protein/nucleic acid aggregates, uses thereof
03/14/2002WO2002020059A2 Vibrio cholerae o139 conjugate vaccines
03/14/2002WO2002020058A1 Preparations for oral administration
03/14/2002WO2002020057A2 Flavoring systems for pharmaceutical compositions and methods of making such compositions
03/14/2002WO2002020052A1 Use of lipopeptides for immunotherapy of hiv-positive subjects
03/14/2002WO2002020047A2 Chlamydial peptides and their mimics in demyelinating disease
03/14/2002WO2002020034A1 'pseudo'-native chemical ligation
03/14/2002WO2002020033A1 Polymer-modified synthetic proteins
03/14/2002WO2002020026A2 Treatment of drug resistant organisms with nitric oxide
03/14/2002WO2002020025A1 Helium-oxygen mixture with therapeutic application
03/14/2002WO2002020020A1 Exemestane as chemopreventing agent
03/14/2002WO2002020018A1 Tablets containing epinastine manufactured by direct compression
03/14/2002WO2002020004A1 Methods for inhibiting inflammatory disease
03/14/2002WO2002020000A2 Combined estrogen blockade of the breast with exemestane and raloxifene
03/14/2002WO2002019990A1 Modified release formulation
03/14/2002WO2002019987A1 Dry-powder film coating composition and method of preparation
03/14/2002WO2002019986A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
03/14/2002WO2002019972A2 Stabilized ascorbic acid solutions
03/14/2002WO2002019969A2 (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
03/14/2002WO2002019963A2 Synthetic erythropoiesis stimulating proteins
03/14/2002WO2001093890A3 Botulinum toxin implant
03/14/2002WO2001093827A3 Neurotoxin implant
03/14/2002WO2001078696A3 Formulations for use in inhaler devices
03/14/2002WO2001078695A3 Pharmaceutical formulations for dry powder inhalers
03/14/2002WO2001078694A3 Formulations for use in inhaler devices
03/14/2002WO2001076644A3 Lipid-based systems for targeting diagnostic agents
03/14/2002WO2001076555A3 Lipid-based drug delivery systems for topical application
03/14/2002WO2001068129A3 Adjuvant for vaccines
03/14/2002WO2001066149A3 Nucleic acid formulations for gene delivery and methods of use
03/14/2002WO2001066093A3 Sustained release ranolazine formulations
03/14/2002WO2001066081A3 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
03/14/2002WO2001064163A3 An improved herbal composition having antiallergic properties and a process for the preparation thereof
03/14/2002WO2001062774A3 Purified lh
03/14/2002WO2001052897A3 Therapeutic anti-inflammatory and analgesic composition containing selective cox-2 inhibitors
03/14/2002WO2001052826A3 Novel podophyllotoxin compositions
03/14/2002WO2001049264A3 Pharmaceutical compositions for oral administration
03/14/2002WO2001045743A3 Use of an enzyme to improve the resorption of medicaments in the tissue
03/14/2002WO2001034113A3 Apparatus and method for preparing microparticles
03/14/2002WO2001032130A3 Phenyl amine carboxylic acid compounds and compositions for delivering active agents
03/14/2002WO2001023001A3 Rapid peg-modification
03/14/2002WO2001002018A3 Compounds that associate on the intermolecular level and aggregate bodies that contain them
03/14/2002US20020032331 Bioactive derivatives of camptothecin
03/14/2002US20020032325 4-amino-3-mercapto-1,2,4-triazoles
03/14/2002US20020032316 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
03/14/2002US20020032301 Process for gelling aqueous media, use of copolyesters as gelling agents for aqueous media and new gelling copolyesters for aqueous media
03/14/2002US20020032281 Crosslinked polymeric structure that degrades in aqueous solution and releases into the solution conjugates of a bioactive agent and a substantially nonpeptidic polymer.
03/14/2002US20020032245 Ion exchange resin loaded with an active substance anisotropically distributed throughout said ion exchange resin particle; rapid release
03/14/2002US20020032243 Novel inverse latices self-invertible with respect to fatty acid esters, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising them
03/14/2002US20020032236 Method for the treatment of dermatological diseases by using nimesulide
03/14/2002US20020032217 Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
03/14/2002US20020032213 Macrolides
03/14/2002US20020032212 A tricyclic compound (with oxy and nitrogen atoms in the ring); perticularly useful for treating or preventing psoriasis and other skin diseases
03/14/2002US20020032201 Compositions containing alpha-2-adrenergic agonist components
03/14/2002US20020032166 Biocompatible cationic detergents and uses therefor
03/14/2002US20020032165 Microspheres and adjuvants for DNA vaccine delivery
03/14/2002US20020032161 Cyclodextrin compositions
03/14/2002US20020032159 Lyophilized compositions containing sphingoglycolipid and process for preparing them
03/14/2002US20020032149 Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism
03/14/2002US20020031820 Enzyme suppressor; for use in the treatment of inflammation, cancer, cardiovascular, endocrine disorders, immunomodulation, alzheimer's disease, diabetes and restenosis
03/14/2002US20020031781 Signal enhancement of bispecific antibody-polymer probe for immunoassay use
03/14/2002US20020031763 Complexing
03/14/2002US20020031560 Stabilized St. John's wort; antidepressant
03/14/2002US20020031558 Preparation of aqueous clear solution dosage forms with bile acids
03/14/2002US20020031556 Mixture of acid, tin pyrophosphate, salicylic acid and glycerides
03/14/2002US20020031552 Teste masked pharmaceutical particles
03/14/2002US20020031548 Pharmaceutical compositions of estrogenic agents
03/14/2002US20020031545 Sustained-release preparation
03/14/2002US20020031544 Antiinflammatory agents
03/14/2002US20020031527 Bulking agents, cryoprotectants and lyoprotectants added for storage stability
03/14/2002US20020031526 Reacting with a base to form a de-n-acetylated product, and depolymerizing with a nitrosation agent
03/14/2002US20020031507 Treatment of inflammatory processes of the intestine, hypercholesterolaemia and infections with Helicobacter pylori; anticarcinogenic agent
03/14/2002US20020031492 Providing a brain tumor sample, quantifying the expression of an interleukin-13 (IL-13) receptor in the sample; and correlating the quantity of expression of the IL-13 receptor with the tumor type or grade; prognosis
03/14/2002US20020031490 Method for preparing resinates
03/14/2002US20020031480 Aerosolizing a hydrofluoroalkane (HFA)/THC composition to provide droplets respirable by a lung of a patient, and administering; inhalers; treating pain, cachexia, migraines, nausea,muscle spasticity
03/14/2002DE10041479A1 Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 Novel pharmaceutical composition for the administration of N-0923
03/14/2002DE10041478A1 Neue pharmazeutische Zusammensetzung New pharmaceutical composition
03/14/2002DE10040707A1 Injectable aqueous medicament, containing colloid, e.g. hydroxyethyl starch, to modulate mobility, diffusion, pharmacokinetic and electrophoretic properties of active agent and improve effectiveness
03/14/2002DE10030378A1 Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen New pharmaceutical composition for topical application of water-insoluble and / or poorly water-soluble drugs
03/14/2002CA2730627A1 Human and mouse targeting peptides identified by phage display
03/14/2002CA2453050A1 Degradable polyacetal polymers
03/14/2002CA2422506A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
03/14/2002CA2421409A1 Use of lipopeptides for immunotherapy of hiv-positive subjects
03/14/2002CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil)
03/14/2002CA2421271A1 Human and mouse targeting peptides identified by phage display
03/14/2002CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides
03/14/2002CA2421195A1 Compositions and methods for targeting peptides in humans in vivo
03/14/2002CA2421191A1 Methods and compositions for in vitro targeting
03/14/2002CA2421179A1 Acid-sensitive compounds, preparation and uses thereof
03/14/2002CA2421070A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma
03/14/2002CA2419590A1 Exemestane as chemopreventing agent
03/14/2002CA2417660A1 Vp22 protein/nucleic acid aggregates, uses thereof
03/14/2002CA2417258A1 Flavoring systems for pharmaceutical compositions and methods of making such compositions
03/14/2002CA2412279A1 "pseudo"-native chemical ligation
03/14/2002CA2412278A1 Polymer-modified synthetic proteins
03/14/2002CA2412277A1 Synthetic erythropoiesis stimulating proteins
03/13/2002EP1186626A1 Composition for soluble films with a new hydrolyzed polysaccharide
03/13/2002EP1186302A1 Ocular tension lowering composition for topical adminstration
03/13/2002EP1186289A2 Method and agent for enhancing diffusivity and long-lasting property of fragrance.
03/13/2002EP1186245A2 Carotenoid esters
1 ... 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 ... 1712